Intracellular signaling during skeletal muscle atrophy

Muscle and Nerve

Volumn 33, Issue 2, 2006, Pages 155-165

  Kandarian, Susan C ^a   Jackman, Robert W ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

FOXO; Inactivity; Muscle wasting; NF kappaB; PI3K Akt; Ubiquitin ligases

Indexed keywords

CASPASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN; TRANSCRIPTION FACTOR FOXO; UBIQUITIN PROTEIN LIGASE;

CACHEXIA; DIET RESTRICTION; ENZYME ACTIVITY; GENE TARGETING; GENETIC TRANSCRIPTION; MOBILIZATION; MUSCLE ATROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; REVIEW; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CASPASES; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUSCLE PROTEINS; MUSCLE, SKELETAL; MUSCULAR ATROPHY; NF-KAPPA B; PEPTIDE SYNTHASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES;

EID: 32144457727     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.20442     Document Type: Review

References (94)

1. Adams V, Jiang H, Yu J, Mobius-Winkler S, Fiehn E, Linke A, et al. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J Am Coll Cardiol 1999;33:959-965.
2. Agarwal A, Das K, Lerner N, Sathe S, Cicek M, Casey G, et al. The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin. Oncogene 2005;24:1021-1031.
3. Allen DL, Linderman JK, Roy RR, Bigbee AJ, Grindeland RE, Mukku V, et al. Apoptosis: a mechanism contributing to remodeling of skeletal muscle in response to hindlimb unweighting. Am J Physiol 1997;273:C579-C587.
4. Allen DL, Roy RR, Edgerton VR. Myonuclear domains in muscle adaptation and disease. Muscle Nerve 1999;22:1350-1360.
5. Attaix D, Combaret L, Tilignac T, Taillandier D. Adaptation of the ubiquitin-proteasome proteolytic pathway in cancer cachexia. Mol Biol Rep 1999;26:77-82.
6. Baldwin AS Jr. The NF-kappaB and IkappaB proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-683.
7. Baracos VE. Management of muscle wasting in cancer-associated cachexia: understanding gained from experimental studies. Cancer 2001;92:1669-1677.
8. Bates PW, Miyamoto S. Expanded nuclear roles for IkappaBs. Sci STKE 2004;2004:pe48.
9. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001;294:1704-1708.
10. Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R, et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 2001;3:1014-1019.
11. Cai D, Frantz JD, Tawa NE Jr, Melendez PA, Oh BC, Lidov HG, et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 2004;119:285-298.
12. Centner T, Yano J, Kimura E, McElhinny AS, Pelin K, Witt CC, et al. Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domain. J Mol Biol 2001;306:717-726.
13. Chen LF, Greene WC. Shaping the nuclear action of NF-kappaB. Nat Rev Mol Cell Biol 2004;5:392-401.
14. Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shiyanova T, et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev 2001;15:2203-2208.
15. Costelli P, Baccino FM. Cancer cachexia: from experimental models to patient management. Curr Opin Clin Nutr Metab Care 2000;3:177-181.
16. Dai KS, Liew CC. A novel human striated muscle RING zinc finger protein, SMRZ, interacts with SMT3b via its RING domain. J Biol Chem 2001;276:23992- 23999.
17. Du J, Wang X, Miereies C, Bailey JL, Debigare R, Zheng B, et al. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest 2004;113:115-123.
18. Fitts RH, Riley DR, Widrick JJ. Physiology of a microgravity environment invited review: microgravity and skeletal muscle. J Appl Physiol 2000;89:823-839.
19. Frenette J, Cai B, Tidball JG. Complement activation promotes muscle inflammation during modified muscle use. Am J Pathol 2000;156:2103-2110.
20. Fujita T, Nolan GP, Liou HC, Scott ML, Baltimore D. The candidate proto-oncogene bcl-3 encodes a transcriptional co-activator that activates through NF-kappa B p50 homodimers. Genes Dev 1993;7:1354-1363.
21. Ghosh S, May MJ, Kopp EB. NF-kappaB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-260.
22. Giresi PG, Stevenson EJ, Theilhaber J, Koncarevic A, Parkington J, Fielding RA, et al. Identification of a molecular signature of sarcopenia. Physiol Genomics 2005;21:253-263.
23. Glass DJ. Molecular mechanisms modulating muscle mass. Trends Mol Med 2003;9:344-350.
24. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 2001;98:14440-14445.
25. Gotthardt M, Hammer RE, Hubner N, Monti J, Witt CC, McNabb M, et al. Conditional expression of mutant M-line titins results in cardiomyopathy with altered sarcomere structure. J Biol Chem 2003;278:6059-6065.
26. Grater F, Shen J, Jiang H, Gautel M, Grubmuller H. Mechanically induced titin kinase activation studied by force-probe molecular dynamics simulations. Biophys J 2005;88:790-804.
27. Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin AS Jr. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000;289:2363-2366.
28. Haddad F, Roy RR, Zhong H, Edgerton VR, Baldwin KM. Atrophy responses to muscle inactivity. II. Molecular markers of protein deficits. J Appl Physiol 2003;95:791-802.
29. Hasselgren PO, Fischer JE. Regulation by insulin of muscle protein metabolism during sepsis and other catabolic conditions. Nutrition 1992;8:434-439.
30. Hasselgren PO, Fischer JE. Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation. Ann Surg 2001;233:9-17.
31. Heissmeyer V, Krappmann D, Wulczyn FG, Scheidereit C. NF-kappaB p105 is a target of IkappaB kinases and controls signal induction of Bcl-3-p50 complexes. EMBO J 1999;18:4766-4778.
32. Hornberger TA, Hunter RB, Kandarian SC, Esser KA. Regulation of translation factors during hindlimb unloading and denervation of skeletal muscle in rats. Am J Physiol Cell Physiol 2001;281:C179-C187.
33. Hunter RB, Kandarian SC. Disruption of either the Nfkb1 or the Bcl3 gene inhibits skeletal muscle atrophy. J Clin Invest 2004;114:1504-1511.
34. Hunter RB, Stevenson E, Koncarevic A, Mitchell-Felton H, Essig DA, Kandarian SC. Activation of an alternative NF-kappaB pathway in skeletal muscle during disuse atrophy. FASEB J 2002;16:529-538.
35. Jackman RW, Kandarian SC. The molecular basis of skeletal muscle atrophy. Am J Physiol Cell Physiol 2004;287:C834-C843.
36. Jagoe RT, Goldberg AL. What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? Curr Opin Clin Nutr Metab Care 2001;4:183-190.
37. Kamei Y, Mizukami J, Miura S, Suzuki M, Takahashi N, Kawada T, et al. A forkhead transcription factor FKHR upregulates lipoprotein lipase expression in skeletal muscle. FEBS Lett 2003;536:232-236.
38. Kamei Y, Miura S, Suzuki M, Kai Y, Mizukami J, Taniguchi T, et al. Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J Biol Chem 2004;279:41114-41123.
39. Kandarian SC, Stevenson EJ. Molecular events in skeletal muscle during disuse atrophy. Exerc Sport Sci Rev 2002;30:111-116.
40. Kawamura I, Morishita R, Tomita N, Lacey E, Aketa M, Tsujimoto S, et al. Intratumoral injection of oligonucleotides to the NF-kappaB binding site inhibits cachexia in a mouse tumor model. Gene Ther 1999;6:91-97.
41. Kedar V, McDonough H, Arya R, Li HH, Rockman HA, Patterson C. Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I. Proc Natl Acad Sci USA 2004;101:18135-18140.
42. Krasnoff J, Painter P. The physiological consequences of bed rest and inactivity. Adv Ren Replace Ther 1999;6:124-132.
43. Lange S, Xiang F, Yakovenko A, Vihola A, Hackman P, Rostkova E, et al. The kinase domain of titin controls muscle gene expression and protein turnover. Science 2005;308:1599-1603.
44. Latres E, Amini AR, Amini AA, Griffiths J, Martin FJ, Wei Y, et al. Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J Biol Chem 2005;280:2737-2744.
45. Lecker SH, Solomon V, Mitch WE, Goldberg AL. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr 1999;129(Suppl):227S-237S.
46. Lecker SH, Solomon V, Price SR, Kwon YT, Mitch WE, Goldberg AL. Ubiquitin conjugation by the N-end rule pathway and mRNAs for its components increase in muscles of diabetic rats. J Clin Invest 1999;104:1411-1420.
47. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 2004;18:39-51.
48. Lee SW, Dai G, Hu Z, Wang X, Du J, Mitch WE. Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol 2004;15:1537-1545.
49. Leeuwenburgh C, Gurley CM, Strotman BA, Dupont-Versteegden EE. Age-related differences in apoptosis with disuse atrophy in soleus muscle. Am J Physiol Regul Integr Comp Physiol 2005;288:R1288-R1296.
50. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W. Mono-versus polyubiquitination: differential control of p53 fate by Mdm2. Science 2003;302:1972-1975.
51. Li YP, Chen Y, Li AS, Reid MB. Hydrogen peroxide stimulates ubiquitin-conjugating activity and expression of genes for specific E2 and E3 proteins in skeletal muscle myotubes. Am J Physiol Cell Physiol 2003;285:C806-C812.
52. Li YP, Chen Y, John J, Moylan J, Jin B, Mann DL, et al. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J 2005;19:362-370.
53. Lingbeck JM, Trausch-Azar JS, Ciechanover A, Schwartz AL. Determinants of nuclear and cytoplasmic ubiquitin-mediated degradation of MyoD. J Biol Chem 2003;278:1817-1823.
54. Lundholm K, Bylund AC, Holm J, Schersten T. Skeletal muscle metabolism in patients with malignant tumor. Eur J Cancer 1976;12:465-473.
55. McCall GE, Allen DL, Linderman JK, Grindeland RE, Roy RR, Mukku VR, et al. Maintenance of myonuclear domain size in rat soleus after overload and growth hormone/IGF-1 treatment. J Appl Physiol 1998;84:1407-1412.
56. McElhinny AS, Kakinuma K, Sorimachi H, Labeit S, Gregorio CC. Muscle-specific RING finger-1 interacts with titin to regulate sarcomeric M-line and thick filament structure and may have nuclear functions via its interaction with glucocorticoid modulatory element binding protein-1. J Cell Biol 2002;157:125-136.
57. McKinnell IW, Rudnicki MA. Molecular mechanisms of muscle atrophy. Cell 2004;119:907-910.
58. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 1996;335:1897-1905.
59. Mitch WE, Price SR. Transcription factors and muscle cachexia: is there a therapeutic target? Lancet 2001;357:734-735.
60. Pattison JS, Folk LC, Madsen RW, Childs TE, Booth FW. Transcriptional profiling identifies extensive downregulation of extracellular matrix gene expression in sarcopenic rat soleus muscle. Physiol Genomics 2003;15:34-43.
61. Pattison JS, Folk LC, Madsen RW, Childs TE, Spangenburg EE, Booth FW. Expression profiling identifies dysregulation of myosin heavy chains IIb and IIx during limb immobilization in the soleus muscles of old rats. J Physiol (Lond) 2003;553:357-368.
62. Peng XD, Xu PZ, Chen ML, Hahn-Windgassen A, Skeen J, Jacobs J, et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 2003;17:1352-1365.
63. Pizon V, Iakovenko A, Van Der Ven PF, Kelly R, Fatu C, Furst DO, et al. Transient association of titin and myosin with microtubules in nascent myofibrils directed by the MURF2 RING-finger protein. J Cell Sci 2002;115:4469-4482.
64. Porter MM, Vandervoort AA, Lexell J. Aging of human muscle: structure, function and adaptability. Scand J Med Sci Sports 1995;5:129-142.
65. Reid MB, Li YP. Tumor necrosis factor-alpha and muscle wasting: a cellular perspective. Respir Res 2001;2:269-272.
66. Reynolds TH, Bodine SC, Lawrence JC Jr. Control of Ser2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load. J Biol Chem 2002;277:17657-17662.
67. Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 2001;3:1009-1013.
68. Sacheck JM, Ohtsuka A, McLary SC, Goldberg AL. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab 2004;287:E591-E601.
69. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004;117:399-412.
70. Sartorelli V, Fulco M. Molecular and cellular determinants of skeletal muscle atrophy and hypertrophy. Sci STKE 2004;2004:re11.
71. Shcherbik N, Haines DS. Ub on the move. J Cell Biochem 2004;93:11-19.
72. Siu PM, Alway SE. Mitochondria-associated apoptotic signalling in denervated rat skeletal muscle. J Physiol (Lond) 2005;565:309-323.
73. Siu PM, Pistilli EE, Butler DC, Alway SE. Aging influences cellular and molecular responses of apoptosis to skeletal muscle unloading. Am J Physiol Cell Physiol 2005;288:C338-C349.
74. Solomon V, Goldberg AL. Importance of the ATP-ubiquitin-proteasome pathway in the degradation of soluble and myofibrillar proteins in rabbit muscle extracts. J Biol Chem 1996;271:26690-26697.
75. Solomon V, Lecker SH, Goldberg AL. The N-end rule pathway catalyzes a major fraction of the protein degradation in skeletal muscle. J Biol Chem 1998;273:25216-25222.
76. Solomon V, Baracos V, Sarraf P, Goldberg AL. Rates of ubiquitin conjugation increase when muscles atrophy, largely through activation of the N-end rule pathway. Proc Natl Acad Sci USA 1998;95:12602-12607.
77. Song YH, Li Y, Du J, Mitch WE, Rosenthal N, Delafontaine P. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 2005;115:451-458.
78. Spencer JA, Eliazer S, Ilaria RL Jr, Richardson JA, Olson EN. Regulation of microtubule dynamics and myogenic differentiation by MURF, a striated muscle RING-finger protein. J Cell Biol 2000;150:771-784.
79. Stein T, Schluter M, Galante A, Soteropoulos P, Tolias P, Grindeland R, et al. Energy metabolism pathways in rat muscle under conditions of simulated microgravity. J Nutr Biochem 2002;13:471.
80. Stevenson EJ, Giresi PG, Koncarevic A, Kandarian SC. Global analysis of gene expression patterns during disuse atrophy in rat skeletal muscle. J Physiol (Lond) 2003;551:33-48.
81. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004;14:395-403.
82. Tawa NE Jr, Odessey R, Goldberg AL. Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles. J Clin Invest 1997;100:197-203.
83. Taylor JM, Crack PJ, Gould JA, Ali U, Hertzog PJ, Iannello RC. Akt phosphorylation and NFkappaB activation are counter-regulated under conditions of oxidative stress. Exp Cell Res 2004;300:463-475.
84. Thomason DB, Booth FW. Atrophy of the soleus muscle by hindlimb unweighting. J Appl Physiol 1990;68:1-12.
85. Thomason DB, Biggs RB, Booth FW. Protein metabolism and beta-myosin heavy-chain mRNA in unweighted soleus muscle. Am J Physiol 1989;257:R300-R305.
86. Tintignac LA, Lagirand J, Batonnet S, Sirri V, Leibovitch MP, Leibovitch SA. Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. J Biol Chem 2005;280:2847-2856.
87. Tisdale MJ. Cancer cachexia: metabolic alterations and clinical manifestations. Nutrition 1997;13:1-7.
88. Tran H, Brunet A, Griffith EC, Greenberg ME. The many forks in FOXO's road. Sci STKE 2003;2003:RE5.
89. Tskhovrebova L, Trinick J. Titin: properties and family relationships. Nat Rev Mol Cell Biol 2003;4:679-689.
90. Watanabe N, Iwamura T, Shinoda T, Fujita T. Regulation of NFkB1 proteins by the candidate oncoprotein Bcl-3: generation of NF-kappaB homodimers from the cytoplasmic pool of p50-p105 and nuclear translocation. EMBOJ 1997;16:3609-3620.
91. Welle S, Brooks AI, Delehanty JM, Needler N, Thornton CA. Gene expression profile of aging in human muscle. Physiol Genomics 2003;14:149-159.
92. Whitehouse AS, Tisdale MJ. Increased expression of the ubiquitin-proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-kappaB. Br J Cancer 2003;89:1116-1122.
93. Wyke SM, Tisdale MJ. NF-kappaB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle. Br J Cancer 2005;92:711-721.
94. Yamamoto Y, Gaynor RB. IkappaB kinases: key regulators of the NF-kappaB pathway. Trends Biochem Sci 2004;29:72-79.